Analysis of the efficacy of giritinib (segatan) in patients with acute monocytic leukemia

Gilitinib (Gilteritinib) is an oral small molecule FLT3 tyrosine kinase inhibitor, mainly targeting FLT3-I Patients with acute myeloid leukemia (AML) with TD or FLT3-TKD mutations. FLT3Mutation is one of the most common genetic abnormalities in AML and is often associated with high disease recurrence rates and poor prognosis. Giritinib inhibits the FLT3 signaling pathway and blocks the proliferation and survival of leukemia cells, thereby achieving anti-tumor effects and providing a new treatment option for patients with relapsed or refractory AML.

In keyADMIRAL In phase III clinical studies, patients with relapsed or refractory AML were treated with giritinib, and the median overall survival was (OS ) was about 9.3 months, which was significantly longer than 5.6 months in the chemotherapy group. The objective response rate (ORR) is approximately 34%, of which the complete response rate (CR) is approximately 21%. The study also showed that for patients with first relapse and FLT3 mutations, giritinib can quickly reduce the proportion of leukemia cells in the bone marrow, creating opportunities for subsequent hematopoietic stem cell transplantation.

In real-world settings, there are individual differences in patient response to giritinib. Some patients reported significant improvements in blood counts, reduced risk of recurrence, and good tolerance; however, some patients also experienced bone marrow suppression, fever, or abnormal liver function in the early stages of treatment, requiring dose adjustment or symptomatic treatment. Overall, giritinib shows stable anti-leukemia activity in patients with FLT3 mutated AML and is convenient for oral administration, helping long-term management and improving quality of life.

Clinically, giritinib is suitable for patients with relapsed or refractory AML, especially those with FLT3Mutants. During use, blood images, liver and kidney functions, and electrocardiogram should be monitored regularly to detect drug-related adverse reactions in a timely manner. For some patients with insufficient efficacy, combined treatment with other targeted drugs or hematopoietic stem cell transplantation can be performed under the guidance of specialist physicians. Overall, giritinib provides an effective targeted therapy for AML patients, improves prognosis, and brings new survival opportunities to high-risk groups.

Reference materials:https://www.drugs.com/